...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Communications >rs11046147 mutation in the promoter region of lactate dehydrogenase-B as a potential predictor of prognosis in triple-negative breast cancer
【24h】

rs11046147 mutation in the promoter region of lactate dehydrogenase-B as a potential predictor of prognosis in triple-negative breast cancer

机译：乳酸脱氢酶-B启动子区域的突变在三重阴性乳腺癌预后的潜在预测因子

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by a deficiency in the expression of three well-known biomarkers of breast cancers, namely estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Its treatment has become an important clinical challenge because TNBC is more aggressive than other breast cancer subtypes, and is usually associated with higher tumor recurrence and lower survival rate [1-3]. Breast cancer patients with ER, PR, and/or HER2 positive tumors often respond positively to targeted therapies whereas TNBC patients remain unresponsive to conventional treatment due to lack of specific biomarkers for determining appropriate treatment (e.g. trastuzumab-based therapy). Hence, identifying novel and effective biomarkers for predicting TNBC prognosis and to improve their survival has become an urgent need for developing effective targeted therapy against TNBC.
机译：三阴性乳腺癌（TNBC）是一种异质疾病，其特征在于患乳腺癌的三种众所周知的生物标志物，即雌激素受体（ER），孕酮受体（PR）和人表皮生长因子受体2（ HER2）。 它的治疗已成为重要的临床挑战，因为TNBC比其他乳腺癌亚型更具侵略性，并且通常与肿瘤复发和降低存活率[1-3]相关。 患有ER，PR和/或HER2阳性肿瘤的乳腺癌患者常常对靶向疗法响应，而TNBC患者由于缺乏特异性生物标志物而仍然对常规治疗仍然对常规治疗进行了反应，用于确定合适的处理（例如曲妥珠菇的疗法）。 因此，鉴定用于预测TNBC预后和改善其存活的新型和有效的生物标志物已成为对TNBC进行有效靶向治疗的迫切需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号